نتایج جستجو برای: ژن npm1

تعداد نتایج: 16927  

Journal: :Haematologica 2013
Tim Pfeiffer Michael Schleuning Jiri Mayer Karl-Heinz Haude Johanna Tischer Stefanie Buchholz Donald Bunjes Gesine Bug Ernst Holler Ralf G Meyer Hildegard Greinix Christof Scheid Maximilian Christopeit Susanne Schnittger Jan Braess Günter Schlimok Karsten Spiekermann Arnold Ganser Hans-Jochem Kolb Christoph Schmid

Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal karyotype. Whereas these subgroups are known to play an important role in outcome in first complete remission, and also in the indication for allogeneic stem cell transplanta...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
W-C Chou H-A Hou C-Y Liu C-Y Chen L-I Lin Y-N Huang Y-C Chao C-A Hsu C-F Huang H-F Tien

BACKGROUND The level of minimal residual disease (MRD) in acute myeloid leukemia (AML) at early time points (TPs) may be an important prognostic factor. Although internal tandem duplication of FLT3 (FLT3-ITD) as an MRD marker has been questioned for its instability based on semi-quantitative methods, we hypothesized that FLT3-ITD dynamics measured by sensitive quantitative real-time PCR at earl...

Journal: :Cancer research 2009
Chizu Tanikawa Koji Ueda Hidewaki Nakagawa Nobuaki Yoshida Yusuke Nakamura Koichi Matsuda

Upon a wide range of cellular stresses, p53 is activated and inhibits malignant transformation through the transcriptional regulation of its target genes related to apoptosis, cell cycle arrest, and DNA repair. However, its involvement in posttranslational modifications of proteins has not yet been well characterized. Here, we report the novel role of p53 in the regulation of protein citrullina...

Journal: :Annals of Oncology 2022

Molecular diagnostics for the detection and characterization of genetic variants is based in majority cases on PCR technology. Since primers probes are designed according to nucleotide sequence DNA region specific mutation, technology can only be applied if mutation well known. In where mutated a gene may have variable sequences, different between patients, set each variant necessary, which inv...

Journal: :Blood 2011
Vera Grossmann Enrico Tiacci Antony B Holmes Alexander Kohlmann Maria Paola Martelli Wolfgang Kern Ariele Spanhol-Rosseto Hans-Ulrich Klein Martin Dugas Sonja Schindela Vladimir Trifonov Susanne Schnittger Claudia Haferlach Renato Bassan Victoria A Wells Orietta Spinelli Joseph Chan Roberta Rossi Stefano Baldoni Luca De Carolis Katharina Goetze Hubert Serve Rudolf Peceny Karl-Anton Kreuzer Daniel Oruzio Giorgina Specchia Francesco Di Raimondo Francesco Fabbiano Marco Sborgia Arcangelo Liso Laurent Farinelli Alessandro Rambaldi Laura Pasqualucci Raul Rabadan Torsten Haferlach Brunangelo Falini

Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1 and CEBPA mutations define World Health Organization 2008 provisional entities accounting for approximately 60% of patients, but the remaining 40% are molecularly poorly characterized. Using whole-exome sequencing of one CN-AML patient lacking mutations in NPM1, CEBPA, FLT3-ITD, IDH1, and MLL-PTD, we newly identi...

Journal: :Journal of clinical pathology 2011
Ilka Warshawsky Frank Mularo

AIMS Detecting low-level clinically significant cancer-relevant somatic mutations can be difficult. Several technologies exist for detecting minority mutations. One method is locked nucleic acid (LNA) PCR. In this study, LNA probes were used to enhance the sensitivity for detecting FLT3 D835/I836 tyrosine kinase domain (TKD) mutations, the JAK2 V617F mutation and insertion mutations in the nucl...

Journal: :Oncotarget 2015
Houria Debarri Delphine Lebon Christophe Roumier Meyling Cheok Alice Marceau-Renaut Olivier Nibourel Sandrine Geffroy Nathalie Helevaut Philippe Rousselot Bérengère Gruson Claude Gardin Marie-Lorraine Chretien Shéhérazade Sebda Martin Figeac Céline Berthon Bruno Quesnel Nicolas Boissel Sylvie Castaigne Hervé Dombret Aline Renneville Claude Preudhomme

Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in n...

Journal: :Medical Science and Discovery 2023

Objective: Acute myeloid leukemia (AML) is characterized by leukemic blasts that are not limited to the bone marrow or peripheral blood, may be presented with granulocytic sarcoma, and cells outside of blood called extramedullary involvement (EMI). Skin, bone, lymph nodes most prevalent locations illness. Granulocytic sarcoma (GS) should considered in differential diagnosis nodules, pustules, p...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه تربیت مدرس - دانشکده علوم پزشکی 1390

بیماری سرطان خون پرومیلوسیتیک حاد (apl) با جابجایی کروموزومی t(15;17) همراه است که منجر به ایجاد پروتئین pml-rara می شود. بررسی مدلهای حیوانی نشان داده اند که اگرچه در این بیماری وجود این پروتئین الحاقی ضروری است ولی به تنهایی برای توسعه بیماری کافی نیست. با مطالعه آرایه های بیماران و مدلهای حیوانی apl نواحی کروموزومی که غالبا" دچار حذف یا تکثیر می شوند انتخاب شدند. 11 ناحیه ژنی شامل tp53، cmyc...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید